Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Kremers Urban Pharmaceuticals was a specialty generic pharmaceutical company focused on developing and manufacturing high-barrier-to-entry generic drugs. The company had a portfolio of over a dozen marketed products—including complex extended-release formulations—and an active pipeline with numerous ANDA filings. It was acquired by Lannett Company in late 2015 for $1.23 billion to expand Lannett’s scale and capabilities in the U.S. generics market.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Kremers Urban Pharmaceuticals.